FDA approves Moderna's new lower-dose Covid-19 vaccine

The FDA approved Moderna's new Covid-19 vaccine, mNexspike, for adults 65 and older and individuals aged 12-64 with heightened risk factors, marking a shift towards next-generation coronavirus vaccines with a lower dose (one-fifth of Spikevax). This approval, based on a study of 11,400 participants, positions mNexspike as a second option alongside Moderna's existing vaccine, though it faces usage limitations similar to Novavax's vaccine due to skepticism from Trump administration officials. Concurrently, the Trump administration canceled funding for Moderna's pandemic flu vaccine development, despite promising early results.

Analysis

Moderna, Inc. (MRNA) has received U.S. Food and Drug Administration (FDA) approval for mNexspike, a new Covid-19 vaccine, representing a development in next-generation vaccine technology due to its significantly lower dosage—one-fifth of the company's existing Spikevax. The approval, based on a study of 11,400 participants demonstrating safety and at least comparable, or in some measures superior, efficacy to the original shot, is limited to adults 65 and older and individuals aged 12 to 64 with specific health conditions that elevate their risk from Covid-19. These restrictions mirror those imposed on Novavax's (NVAX) vaccine and reflect a cautious regulatory stance influenced by skepticism from Health Secretary Robert F. Kennedy Jr. and other Trump administration officials, contrasting with the broader approval of Moderna's original Spikevax. While Moderna plans to offer both mNexspike and Spikevax, potentially catering to a more segmented market, the positive development is tempered by the recent cancellation of U.S. government funding for Moderna's pandemic flu vaccine program, despite promising early study results, which could impact its pipeline diversification efforts.

Key Decisions for Investors

• Investors should assess the incremental revenue potential of mNexspike, factoring in its restricted approved demographic compared to the broadly available Spikevax and similar limitations faced by competitors like Novavax.
• Consider the implications of the current regulatory environment and administrative skepticism on the market penetration and uptake of new vaccine products, even those with demonstrated efficacy.
• Evaluate the impact of the canceled pandemic flu vaccine funding on Moderna's long-term R&D pipeline and its ability to diversify revenue streams beyond Covid-19, despite the approval of mNexspike.